Loading
companiesCompany
Biogen
Biogen is the Massachusetts biotech that, as Biogen Idec, co-developed rituximab, the first antibody approved for cancer; it now concentrates on neurology.
Also called: Biogen Inc.Biogen IdecIDEC Pharmaceuticals
Overview
Biogen, founded in 1978 and headquartered in Cambridge, Massachusetts, merged with IDEC Pharmaceuticals in 2003 to form Biogen Idec. IDEC had developed rituximab (Rituxan) with Genentech, the anti-CD20 antibody approved in 1997 for follicular lymphoma, and Biogen Idec led lymphoma trials for it and for the radiolabelled antibody ibritumomab tiuxetan (Zevalin). The company later returned to the Biogen name and focuses on neurological and rare diseases; its phase 3 cancer trials on ClinicalTrials.gov date from the lymphoma era.
Headquarters
Cambridge, MA, US
Scorecard
All companies#112of 1244 companies, score 47
- approved products +6
- targets +2
- modalities +2
- regions +7
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 2,033 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1978
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)
Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.
Similar pages
- CancerPrimary cutaneous follicle centre lymphoma
Shares Rituximab, Follicular lymphoma, Diffuse large B-cell lymphoma.
- TrialStudy of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Shares Rituximab, Diffuse large B-cell lymphoma.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Rituximab, Follicular lymphoma.
- Key paperRELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma
Shares Rituximab, Follicular lymphoma.
- Key paperGALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma
Shares Rituximab, Follicular lymphoma.
- CompanyMabion
Shares Rituximab, Diffuse large B-cell lymphoma.
- TrialStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Shares Rituximab, Diffuse large B-cell lymphoma.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Rituximab, Follicular lymphoma, Diffuse large B-cell lymphoma.
cancers
drugs
ApprovedMonoclonal antibody (anti-CD20, chimeric)
Rituximab · Rituxan / MabThera (and biosimilars)